Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CNS Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Viral-associated cancers and disorders.
REL overexpression and sustained NF-κB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.
Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.
Prognostic Factors Influencing the Efficacy and Safety of Teclistamab and Elranatamab in Multiple Myeloma: A Multicenter Propensity-Weighted Analysis
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
T cell malignancies after CAR T cell therapy in the DESCAR-T registry.
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.
Neurotoxicity in Patients With CNS Lymphomas Treated With CAR T-Cell Therapy: A Study From the French Oculo-Cerebral Lymphoma Network.
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.
ICE polychemotherapy is an efficient salvage treatment in primary central nervous system lymphoma: an LOC network study.
Author Correction: T cell malignancies after CAR T cell therapy in the DESCAR-T registry.
Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders.
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Circulating tumor cells in Waldenström macroglobulinemia.
Treatment of PTLD: a slow and difficult path.
Epilepsy in Patients With Primary CNS Lymphoma: Prevalence, Risk Factors, and Prognostic Significance.
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
OS06.8.A PROSPECTIVE STUDY ON THE IMPACT OF THE GUT MICROBIOME COMPOSITION TO PATIENT’S RESPONSE TO STANDARD TREATMENT IN PCNSL
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: A LOC network study
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Artificial intelligence classifies and predicts the outcome of primary CNS and nodal large B-cell lymphomas
SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era.
Artificial intelligence classifies and predicts the outcome of primary CNS and nodal large B-cell lymphomas